کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2108098 | 1083721 | 2013 | 16 صفحه PDF | دانلود رایگان |

SummaryThe identification and targeted therapy of cells involved in hepatocellular carcinoma (HCC) recurrence remain challenging. Here, we generated a monoclonal antibody against recurrent HCC, 1B50-1, that bound the isoform 5 of the α2δ1 subunit of voltage-gated calcium channels and identified a subset of tumor-initiating cells (TICs) with stem cell-like properties. A surgical margin with cells detected by 1B50-1 predicted rapid recurrence. Furthermore, 1B50-1 had a therapeutic effect on HCC engraftments by eliminating TICs. Finally, α2δ1 knockdown reduced self-renewal and tumor formation capacities and induced apoptosis of TICs, whereas its overexpression led to enhanced sphere formation, which is regulated by calcium influx. Thus, α2δ1 is a functional liver TIC marker, and its inhibitors may serve as potential anti-HCC drugs.
► 1B50-1, which recognizes α2δ1, identifies HCC tumor-initiating cells
► A surgical margin with cells detected by 1B50-1 correlates with poor HCC prognosis
► α2δ1 is essential in Ca2+ signaling and maintenance of TIC properties
► 1B50-1 has a therapeutic effect on HCC by eradicating α2δ1+ TICs
Journal: - Volume 23, Issue 4, 15 April 2013, Pages 541–556